Safety and Tolerability of TWP-201 in Healthy Female Subjects
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, single dose, escalation, phase
I clinical trial to evaluate the safety and tolerability of recombinant human follicle
stimulating hormone Fc fusion protein injection (TWP-201) in healthy female subjects. The
objective of the trial is to evaluate the safety and tolerability of TWP-201 in healthy
female subjects.